308 related articles for article (PubMed ID: 22868923)
1. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
Ghigna MR; Reineke T; Rincé P; Schüffler P; El Mchichi B; Fabre M; Jacquemin E; Durrbach A; Samuel D; Joab I; Guettier C; Lucioni M; Paulli M; Tinguely M; Raphael M
Pathobiology; 2013; 80(2):53-9. PubMed ID: 22868923
[TBL] [Abstract][Full Text] [Related]
2. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
Johnson LR; Nalesnik MA; Swerdlow SH
Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
5. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
Montone KT; Friedman H; Hodinka RL; Hicks DG; Kant JA; Tomaszewski JE
Mod Pathol; 1992 May; 5(3):292-302. PubMed ID: 1323104
[TBL] [Abstract][Full Text] [Related]
6. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
7. bcl-2 protein is strongly expressed in post-transplant lymphoproliferative disorders.
Chetty R; Biddolph S; Kaklamanis L; Cary N; Stewart S; Giatromanolaki A; Gatter K
J Pathol; 1996 Nov; 180(3):254-8. PubMed ID: 8958801
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.
Capello D; Berra E; Cerri M; Gaidano G
Minerva Med; 2004 Feb; 95(1):53-64. PubMed ID: 15041926
[TBL] [Abstract][Full Text] [Related]
9. Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.
Murray PG; Swinnen LJ; Flavell JR; Ragni MV; Baumforth KR; Toomey SM; Filipovich AH; Lowe D; Schnell CS; Johl J; Gulley M; Young LS; Ambinder RF
Hum Pathol; 2001 Sep; 32(9):963-9. PubMed ID: 11567226
[TBL] [Abstract][Full Text] [Related]
10. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
Zaffiri L; Frankel C; Bush EJ; Neely ML; Pavlisko EN; Mokrova IL; Luftig MA; Palmer SM
J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812
[TBL] [Abstract][Full Text] [Related]
11. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders.
Smir BN; Hauke RJ; Bierman PJ; Gross TG; d'Amore F; Anderson JR; Greiner TC
Lab Invest; 1996 Oct; 75(4):575-88. PubMed ID: 8874388
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus latency patterns in polymorphic lymphoproliferative disorders and lymphomas in immunodeficiency settings: Diagnostic implications.
Volaric AK; Saleem A; Younes SF; Zhao S; Natkunam Y
Ann Diagn Pathol; 2024 Jun; 70():152286. PubMed ID: 38447253
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
15. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorders are not associated with IgG4 sclerosing disease.
Cathro HP; Bullock GC; Bonatti H; Meriden Z; Cook S; Aguilera N
Transpl Infect Dis; 2014 Dec; 16(6):897-903. PubMed ID: 25298125
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
[TBL] [Abstract][Full Text] [Related]
18. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
[TBL] [Abstract][Full Text] [Related]
19. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
20. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
